LAVAL, Quebec, May 19, 2015 /PRNewswire/ -- Valeant
Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today
announced the election of eleven directors nominated at its 2015
annual meeting of shareholders today. The detailed results of
the vote for the election of directors are set out below:
Name
|
|
For
|
|
Withheld
|
|
Broker
Non-Votes
|
|
|
|
|
|
|
|
|
|
Ronald H.
Farmer
|
|
259,517,209
|
|
2,064,596
|
|
12,938,661
|
|
Colleen A.
Goggins
|
|
260,564,263
|
|
1,017,542
|
|
12,938,661
|
|
Robert A.
Ingram
|
|
258,725,145
|
|
2,856,660
|
|
12,938,661
|
|
Anders
Lönner
|
|
259,632,031
|
|
1,949,774
|
|
12,938,661
|
|
Theo
Melas-Kyriazi
|
|
260,811,015
|
|
770,790
|
|
12,938,661
|
|
J. Michael
Pearson
|
|
255,809,687
|
|
5,772,118
|
|
12,938,661
|
|
Robert N.
Power
|
|
258,849,981
|
|
2,731,824
|
|
12,938,661
|
|
Norma A.
Provencio
|
|
260,777,276
|
|
804,529
|
|
12,938,661
|
|
Howard B.
Schiller
|
|
250,437,448
|
|
11,144,357
|
|
12,938,661
|
|
Katharine B.
Stevenson
|
|
260,656,695
|
|
925,110
|
|
12,938,661
|
|
Jeffrey W.
Ubben
|
|
260,166,082
|
|
1,415,723
|
|
12,938,661
|
|
At the annual meeting, shareholders also approved the
non-binding advisory vote on named executive officer compensation
as disclosed in the proxy statement and appointed
PricewaterhouseCoopers LLP as the Company's independent registered
public accounting firm until the close of the Company's 2016 annual
meeting of shareholders.
The final vote tabulation on all matters voted on at today's
meeting will be reported to the U.S. Securities and Exchange
Commission on a current report on Form 8-K and such report will be
made available on the Company's web site, www.valeant.com.
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a
multinational specialty pharmaceutical company that develops,
manufactures and markets a broad range of pharmaceutical products
primarily in the areas of dermatology, eye health, neurology
and branded generics. More information about Valeant can be found
at www.valeant.com.
Contact Information:
Laurie W.
Little
949-461-6002
laurie.little@valeant.com
Logo -
http://photos.prnewswire.com/prnh/20101025/LA87217LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-announces-2015-annual-meeting-results-300085929.html
SOURCE Valeant Pharmaceuticals International, Inc.